Výsledky vyhledávání - "Galina Kharkevich"

Akademický článek

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

BackgroundProlgolimab is the first Russian PD-1 inhibitor approved for the first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was approved in two weight-based regimens of 1 mg/kg Q2W and 3 mg/kg Q3

Externí odkaz: https://doaj.org/article/f9e274f24e4c449f852c192658eb49c8

Zobrazit plný text záznamu

Paclitaxel and carboplatin chemotherapy in patients with metaststic melanoma refractory to BRAF/MEK inhibitors

Autor: Irina Markina, Kristina V. Orlova, Galina Kharkevich, Lev V. Demidov, Natalia N. Petenko, Igor Sinelnikov, Igor Samoylenko, Anastasia S Vikhrova, Igor A Utyashev

Publikováno v: Journal of Clinical Oncology. 34:9552-9552

9552Background: Metastatic melanoma remains a disease with poor prognosis even in patients with BRAF mutation, treated by BRAF/MEK inhibitors. In many countries immune checkpoints inhibitors which ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7acce24ed3381c79f7e4e7fd84637fcb
https://doi.org/10.1200/jco.2016.34.15_suppl.9552

Zobrazit plný text záznamu

Granulocyte-Macrophage Colony-Stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-Risk Renal Cell Carcinoma

Autor: Galina Kharkevich, Ilya Tsimafeyeu, Maria Volkova, Lev V. Demidov, Natalia N. Petenko, Vsevolod Matveev

Publikováno v: Journal of Cancer Science & Therapy.

This prospective, non-randomized study assessed toxicity and potential efficacy of low-dose granulocytemacrophage colony-stimulating factor (GM-CSF), interferon alpha (IFN) and interleukin 2 (IL-2) postoperatively in patients with high-risk renal cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de2f3615bcbb175ad7029c0683def007
https://doi.org/10.4172/1948-5956.1000042

Zobrazit plný text záznamu

Do we have early detection of cutaneous melanoma in Russia? Single-institution observational study

Autor: Igor A Utyashev, Yana V Vishnevskaya, Lev V. Demidov, Kristina V. Orlova, Igor Samoylenko, Galina Kharkevich

Publikováno v: Journal of Clinical Oncology. 32:e20027-e20027

e20027 Background: Despite the quite low melanoma incidence in Russia (approx. 5 per 100 000) mortality rate is very similar to countries with higher incidence (approx. 2 per 100 000). We believe t...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55a6ce188f012c7d079dd163124c3b8a
https://doi.org/10.1200/jco.2014.32.15_suppl.e20027

Zobrazit plný text záznamu

Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine

Autor: G. Z. Chkadua, Lev V. Demidov, Galina Kharkevich, Valery V. Nazarova, Tatiana Zabotina, Olga V. Korotkova, Anastasia S Vikhrova, Igor Samoylenko, Irina N. Mikhaylova

Publikováno v: Journal of Clinical Oncology. 31:e20042-e20042

e20042 Background: The purpose of this sub study was to identify peripheral blood biomarkers associated with the therapeutic effect of immunotherapy with dendritic cell vaccine in patients with metastatic melanoma (MM). Methods: Patients (pts) with l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4f9b740c9abf0c680fbeebb56ecdf81
https://doi.org/10.1200/jco.2013.31.15_suppl.e20042

Zobrazit plný text záznamu

A randomized prospective study of low-dose interleukin-2 (IL-2) in combination with interferon-alpha (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma: Final results

Autor: Ilya Tsimafeyeu, Lev V. Demidov, Galina Kharkevich

Publikováno v: Journal of Clinical Oncology. 25:15643-15643

15643 Background: High and intermediate IL-2 regimens are difficult to recommend because of great toxicity. Based on previous activity of combination low-dose cytokines (including 1 MIU IL-2) in metastatic renal cell carcinoma (MRCC) patients (pts) (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e808d5a4e82a4ca3c16777b4320500eb
https://doi.org/10.1200/jco.2007.25.18_suppl.15643

Zobrazit plný text záznamu

Low molecular weight heparin (LMWH) increases the efficacy of immunotherapy in metastatic renal cell carcinoma patients with abnormal coagulation

Autor: A. Madzhuga, A. Yelizarova, O. Somonova, Lev V. Demidov, Galina Kharkevich, Natalia N. Petenko, Ilya Tsimafeyeu

Publikováno v: Journal of Clinical Oncology. 25:15591-15591

15591 Background: Antitumor effects of LMWH are unclear. Heparin can bind with fibroblast-growth factor, other heparine-binding angiogenic factors, their receptors, and/or impact on coagulation system which induces angiogenesis. We previously reveale

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d3d9255d7b1a5e4deb4a2d65a784a52
https://doi.org/10.1200/jco.2007.25.18_suppl.15591

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání